Stifel analyst Thomas Stephan upgraded Sight Sciences to Buy from Hold with a price target of $15, up from $10. The analyst has a more favorable view on the stock’s near-to-intermediate term setup compared to the long-term. Stephan’s latest survey diligence of 41 minimally invasive glaucoma surgery-trained ophthalmologists gives him increased confidence in the company posting upside to revenue estimates in 2023. He expects a softer competitive landscape for at least the next six months for Sight Sciences.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SGHT:
- Sight Sciences upgraded to Buy from Hold at Stifel
- Sight Sciences, Verana Health collaborate on glaucoma research
- Sight Sciences price target raised to $15 from $10 at Citi
- Improvements in Signs and Symptoms of Dry Eye Disease From a Single TearCare® Treatment Sustained Through 12 Months
- Sight Sciences announces independent data on TearCare treatment
